sellWeak cluster of 410b5-1 plan
Alexandra Balcom sold $2.3M of NUVL
Chief Financial Officer at Nuvalent, Inc.. 27,588 shares at an average of $85.05, traded Sep 29, 2025, filed Oct 1, 2025.
Warning score
37Value
$2.3M
27,588 shares
Holdings after
61,734
-40% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +25Trade size$2.3M at market
- +10Share of holdings soldSold 40% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-227255, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 29, 2025 | MOption exercise Class A Common Stock10b5-1 | +7,588 | $6.89 | $52k | 69,322 | Oct 1, 2025 |
| Sep 29, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -7,588 | $85.01 | $645k | 61,734 | Oct 1, 2025 |
| Sep 30, 2025 | MOption exercise Class A Common Stock10b5-1 | +20,000 | $6.89 | $138k | 81,734 | Oct 1, 2025 |
| Sep 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $85.06 | $1.7M | 61,734 | Oct 1, 2025 |
| Sep 29, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,588 | $0.00 | $0 | 79,638 | Oct 1, 2025 |
| Sep 30, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 59,638 | Oct 1, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $782k 7,084 shares | -11% | |
| 12Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $434k 4,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Matthew Shair director | $820k 7,500 shares | -1% | |
| 55Moderate | Nuvalent, Inc. | James E Flynn director, owner, other | $71M 742,574 shares | -9% | |
| 37Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.1M 20,729 shares | -25% | |
| 30Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $2.6M 24,200 shares | -33% | |
| 30Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $2.2M 21,800 shares | -31% | |
| 11Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $412k 4,000 shares | -8% | |
| 35Weak | Nuvalent, Inc. | Matthew Shair director | $6.0M 60,000 shares | -4% | |
| 12Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $475k 5,000 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.